Literature DB >> 15470683

Psychological and educational factors: better predictors of work status than FEV1 in adults with cystic fibrosis.

Eileen J Burker1, Jan Sedway, Stacia Carone.   

Abstract

Now that more individuals with cystic fibrosis (CF) are living into adulthood, vocational attainment is an increasingly important consideration. Work is a key factor in quality of life. The purpose of the present paper was to evaluate the factors that are associated with work status in 183 adults with CF. Approximately half of the participants were working at the time of evaluation, an impressive figure given that the mean forced expired volume in 1 sec (FEV1) was 31.9%. The average number of hours worked was 32.7 hr/week. The majority of individuals were employed in professional, technical, or managerial occupations (accounting, teaching, law, or social work). A third were employed in clerical and sales occupations, and the remaining individuals were employed in a wide range of other occupations (hotel manager, undercover shopper, artist, or dental technician). Interestingly, FEV1 and age did not differentiate between subjects who were working and those who were not. Individuals who were working had significantly lower depression scores and a higher educational level than those who were not working. Future research is needed to determine whether it is the increased socialization and the resulting social support that may come from a work environment, or a reduction in financial stress because of better income and health benefits that helps to explain this difference. Alternatively, work may serve as a distraction from the symptoms of CF. It is likely that those with higher educational levels had more professional jobs that were more easily modified as health declined. Future research needs to assess how career choices are made, and what factors into a patient's decision to keep working. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15470683     DOI: 10.1002/ppul.20090

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  Screening for symptoms of depression and anxiety in adolescents and young adults with cystic fibrosis.

Authors:  Avani C Modi; Kimberly A Driscoll; Karen Montag-Leifling; James D Acton
Journal:  Pediatr Pulmonol       Date:  2010-11-17

2.  Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life.

Authors:  Casilda Olveira; Gabriel Olveira; Inmaculada Gaspar; Antonio Dorado; Ivette Cruz; Federico Soriguer; Alexandra L Quittner; Francisco Espildora
Journal:  Qual Life Res       Date:  2012-04-29       Impact factor: 4.147

Review 3.  Patient-reported outcomes in cystic fibrosis.

Authors:  Christopher H Goss; Alexandra L Quittner
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 4.  Factors that promote or hinder young disabled people in work participation: a systematic review.

Authors:  T J Achterberg; H Wind; A G E M de Boer; M H W Frings-Dresen
Journal:  J Occup Rehabil       Date:  2009-03-24

5.  A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population.

Authors:  David C Taylor-Robinson; Rosalind Smyth; Peter J Diggle; Margaret Whitehead
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

6.  Factors related to changes in the quality of life among Polish adolescents and adults with cystic fibrosis over a 1-year period.

Authors:  Grażyna Dębska; Henryk Mazurek
Journal:  Patient Prefer Adherence       Date:  2015-12-15       Impact factor: 2.711

7.  International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.

Authors:  Alexandra L Quittner; Janice Abbott; Anna M Georgiopoulos; Lutz Goldbeck; Beth Smith; Sarah E Hempstead; Bruce Marshall; Kathryn A Sabadosa; Stuart Elborn
Journal:  Thorax       Date:  2015-10-09       Impact factor: 9.139

8.  Lived experiences of individuals with cystic fibrosis on CFTR-modulators.

Authors:  Annelise Page; Aaron Goldenberg; Anne L Matthews
Journal:  BMC Pulm Med       Date:  2022-01-21       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.